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AbsTrACT
Objective In intensive care units numerous drugs 
have to be infused simultaneously, resulting inline 
incompatibility. Propofol is formulated as a lipid 
emulsion and it is well known that electrolytes can affect 
the stability of an emulsion system. Our goal was to 
evaluate and to compare the physical compatibility of 
three commercial propofol lipid emulsions of different 
manufacturers, mixing them with the most commonly 
used crystalloids in intensive care units.
Methods Simulated Y-site administration was 
accomplished by mixing the 2% MCT/LCT propofol 
emulsions with the commonly used crystalloids in the 
intensive care unit in a 1:1 ratio in a polypropylene 
syringe. The aliquot samples were evaluated immediately 
and at 15, 30, 60 and 120 min after preparation by 
visual observation, pH and droplet size measurement.
results There was no emulsion breakdown or any 
visible change during the study period. Mixing the 
propofols with crystalloids, 10% magnesium sulphate or 
10% potassium chloride there was no significant change 
in the droplet size compared with the original propofol 
emulsions. A slight alteration in droplet size was noticed 
in a few of the propofol samples, when magnesium, 
potassium or both were the secondary additives to the 
crystalloids, but this is not considered clinically relevant.
Conclusion The physical properties of emulsions are 
determined by component, therefore the compatibility 
data in literature has to be evaluated prudently. All three 
commercially available MCT/LCT propofol emulsions 
are considered physically compatible with the tested 
crystalloids.
InTrOduCTIOn
Propofol is a widely used sedatohypnotic agent for 
the sedation of intubated, mechanically ventilated 
patients in the intensive care units (ICUs). Its popu-
larity is due to rapid onset, short duration of action 
and minimal side effects.1 
Since propofol is insoluble in water and it cannot 
be administered as aqueous salt, it is formulated as an 
oil-in-water lipid emulsion. Diprivan (AstraZeneca) 
was the first approved injectable propofol emulsion 
and it has become one of the most commonly used 
worldwide. This formulation consists of propofol, 
soybean oil (long-chain triglycerides, LCTs), egg-yolk 
lecithin, glycerol, water, EDTA and sodium hydroxide 
to adjust the pH to 7–8.5.2
In another formulation (Gensia Sicor Pharma-
ceuticals), EDTA was replaced with metabisulphite. 
Since metabisulphite only dissolves in acidic media, 
the pH of this formulation is adjusted to 4.5–6.5. 
This lower pH affects the stability and other phys-
ical characteristics of the emulsion3. Metabisulphite 
has been also reported to support lipid peroxida-
tion in propofol emulsion and to cause allergic 
reactions.4 Currently available newer formula-
tions of propofol (B.Braun, Fresenius Kabi) are 
preservative-free and contain mixed medium chain 
triglycerides (MCTs)—long chain triglycerides 
(LCTs).5 6 It was reported that this formulation did 
not affect the pharmacokinetics or pharmacody-
namics of propofol and was found to cause less pain 
on injection.7 8
Lipid macroemulsions are thermodynamically 
unstable, therefore maintaining long-term stability 
is a major challenge. The stability of an emulsion 
depends ultimately on the interfacial tension and 
the droplet size. Other contributing factors to 
stability of the emulsion are density, viscosity, zeta 
potential and temperature. Furthermore, type of 
the emulsifier component, applied lipids and pH 
can influence the physicochemical stability of lipid 
emulsions.9 Any change in the structure of emulsion 
can lead to different types of emulsion instability eg. 
flocculation, creaming, coalescence or breaking.10
Critically ill patients are treated with complex 
intravenous medications. The majority of the 
patients admitted to the ICU requires sedation 
for which mainly propofol is used. The most 
commonly used medications, beside propofol, are 
the opioid analgesics, antibiotics, vasopressors, 
antihypertensive agents. The use of crystalloids 
are also essential to ensure the adequate hydra-
tion of patients. Crystalloids are aqueous solutions 
of mineral salts or other water-soluble molecules. 
Despite of the presence of multilumen central vein 
catheter (CVC), different medications, including 
crystalloids, are often co-infused in the same line 
which may produce the likelihood of incompat-
ibility. Incompatibility can involve precipitation, 
ionic reactions, evolution of gas and denaturation 
of biological molecules. This can cause decreased 
drug effectiveness or increased microparticle load 
with well-documented consequences, such as thera-
peutic failure, catheter occlusion or embolism.11–14 
It has been previously reported that fat embolism 
occured, when propofol was mixed with lidocain.15 
The compatibility of propofol with other drugs 
has been investigated by other authors, however, 
in these studies the LCT formulations of propofol 
(Diprivan and its generics) were tested, not the 
newer MCT/LCT formulation.16 To our best 
knowledge, there is no published data concerning 
the compatibility of MCT/LCT propofol and crys-
talloids, furthermore mixing of propofol with other 
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infusions is not recommended by the manufacturers.5 6 17 Despite 
the warnings of manufacturer the co-administration of infusions 
is common in the clinical practice because of limited intravenous 
access. Our goal was to evaluate and to compare the physical 
compatibility of three commercial MCT/LCT propofol emul-
sions from different manufacturers, mixing them with the most 
commonly used crystalloids in the intensive care. Based on our 
stability results, we make conclusions on the use of mixtures in 
clinical practice. 
MATerIAl And MeThOds
For this study we used three different propofol products and 
four crystalloids that are available on the Hungarian market. 
The propofol emulsions are manufactured by B.Braun (BB), 
Fresenius-Kabi (FK) and UAB Norameda (UAB). In the ICU 
20 mg/mL (2%) propofol is used, therefore we decided to 
investigate this concentration. Compositions of commer-
cially available propofol products and Diprivan (AstraZeneca) 
(which is not available on the Hungarian market) are compared 
in table 1. The electrolyte content of crystalloids are listed in 
table 2.
sample preparation
The study samples were static admixtures of crystalloids and 
propofol with a ratio of 1:1 (v/v). First, a 5 mL sample of 2% 
propofol emulsion was combined individually with 5 mL of 
crystalloids, 5 ml of 10% magnesium sulphate (Pharmamagist 
Kft., Budapest) or 5 ml 10% potassium chloride (Pharmam-
agist Kft., Budapest) in a colourless 20 mL polypropylene 
syringe (B.Braun, Omnifix). Second, eligible amount of 10% 
magnesium sulphate and/or 10% potassium chloride was 
added to each crystalloids as a secondary additive making the 
final concentration 4 mg/mL. After this, 5 mL of samples were 
mixed with 5 mL of propofol emulsions in the syringes. In 
all cases the air was evacuated from the syringes, then the 
content was mixed by shaking. The samples were subsequently 
stored at room temperature (25°C) and in daylight in the 
laboratory.
Methods
The pH and the mean droplet size distribution of all three propo-
fols were measured on samples taken out of the original package. 
For the analysis of admixtures, 2 mL of mixed samples were taken 
out of the syringes immediately and at 15, 30, 60 and 120 min after 
preparation, and the following two measurements were done with 
all samples: pH and droplet size measurement. The pH values of 
samples were determined by a portable pH meter equipped with 
an inserting probe (Testo 206-pH2, Testo, Lenzkirch, Germany). 
The pH meter was calibrated using a solution of pH 4 and pH 7 
before each measurement sample series. The volume based drop 
size distribution of the emulsions was measured by laser diffrac-
tion (Mastersizer 2000, Malvern Instruments Ltd., Worcestershire, 
UK) at room temperature (25°C) with the following parameters: 
300 RF lens; small volume dispersion unit (2000 rpm); refractive 
index for dispersed particles 1.596; refractive index for disper-
sion medium 1.330. The size analysis was repeated three times. 
Glycerol-water 1:37 was used as dispersant medium. In all cases, 
the volume weighted drop size distributions, d(0.1), d(0.5), and 
d(0.9) (where for example d(0.5) is the maximum particle diam-
eter below which 50% of the sample volume exists–also known 
as the median particle size by volume) were determined and eval-
uated. During the study the samples were inspected visually with 
unaided eye for obvious degradation of the emulsion and/or oil 
separation. 
resulTs
There was no considerable difference in the pH of the three 
propofols when measured after being taken out of the original 
vials. After mixing with crystalloids, the pH of samples were, 
according to the original pH of crystalloids, between 4.37-7.31 
(figures 1 and 2). The admixtures of the Sterofundin B (SFB) 
and Sterofundin G (SFG) resulted in the lowest pH, due to the 
fact that these infusions originally had a lower pH, which is 
needed to prevent decomposition of their glucose component 
during autoclaving. The mean droplet size of all three propo-
fols were measured and taken out of their original packages 
resulting in no significant difference: BB 0.133 µm, FK 0.136 
µm and UAB 0.135 µm, respectively. The effect of crytalloids to 
droplet size of propofol emulsion are summarised in figure 3. 
Mixing all three propofols with 10% magnesium sulphate or 
10% potassium chloride there was no change in visual appear-
ance and in droplet size despite high electrolyte concentration. 
Furthermore, there was no alteration when mixing the propo-
fols with crystalloids. 
When adding potassium chloride to Ringerfundin (RF) and 
SFB there was a slight alteration in the droplet size of propofol 
of FK and there was no detectable visible change in any of the 
mixed samples. 
The addition of both magnesium and potassium to the crys-
talloids did not result in change in the droplet size when it was 
mixed with the propofol of B or UAB. There was considerable 
increase in the droplet size when the propofol of FK was mixed 
with RF and potassium and magnesium was added, but the 
droplet size remained below 1 µm.
Table 1 Composition of propofol products
AstraZeneca2 b.braun6 Fresenius-Kabi5 uAb norameda17
soybean oil (LCT) + + + +
MCT – + + +
glycerol + + + +
egg-yolk lecithin + + + +
sodium oleate – + – +
oleic acid – – + – 
sodium hydroxide + – + +
water for injection + + + +
EDTA + – – – 
pH 7–8.5 n/a n/a 6–8.5
pH(measured) – 7.9 7.5 7.1
n/a, not available.
Table 2 The electrolyte content of crystalloids
Isolyte 26 ringerfundin27 sterofundin b28 sterofundin G29
Na+ (mmol/l) 137 145 53.7 140
K+ (mmol/l) 4 4 24.2 4
Ca2+(mmol/l) – 2.5 – 2.5
Mg2+(mmol/l) 1.5 1 2.5 1
Cl-(mmol/l) 110 127 50.6 112
PO4
3- (mmol/l) – – 7.3 – 
lactate (mmol/l) – – 25 45
acetate (mmol/l) 34 24 – – 
maleate (mmol/l) – 5 – – 
glucose (g/l) – – 50 50
pH 6.9–7.9 5.1–5.9 4.0–7.0 4.5–7.5
pH (measured) 6.9 5.2 4.5 4.6
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dIsCussIOn
Lipid emulsions are thermodynamically unstable, therefore their 
stability is important for safely administering infusions. Physical 
incompatibility, precipitation of particles or growth of droplet, 
is more relevant for Y-site administration than chemical incom-
patibility, because of the short contact time.11 Both precipitates 
and enlarged oil droplets can cause fatal emboli and harm to 
the liver and lungs.11–14 Furthermore, the droplet surface area 
decrease can cause alteration in the release of propofol in vivo 
due to the enlarged droplet size.18 The quality and safety of 
lipid emulsions has been identified, uniquely among pharma-
copoeia, in the United States Pharmacopoeia (USP) since 2007. 
The USP standards require that the volume weighted percentage 
of fat with droplet diameter above 5 µm (PFAT5) should be ≤ 
0.05%.19 Although lipid emulsions have been in clinical use for 
more than 50 years there is no standardised procedure or 
consensus to which test should be accomplished to evaluate their 
compatibility. Therefore, various methods have also been used to 
investigate their stability, most commonly the visual observation, 
pH, droplet size and zeta potential measurement. According 
to a recent study the best practice testing compatibility of lipid 
emulsions and intravenous drugs is the combination of these 
methods.20 One of the important factors what is considered to 
determine the emulsion stability is the pH, since the H+ ions can 
alter the droplet charge by adsorption to the surface. 
The emulsifier component in all three propofols, beside 
sodium oleate or oleic acid, is the egg-yolk lecithin which is 
a mixture of various phospholipids (PLs). Phosphatidylcho-
line and phosphatidylethanolamine are the major components 
which are unionised at pH 6-8. Other PLs of lecithin such as 
phosphatidylserine and phosphatidylglycerol are negatively 
charged at this pH, ensuring negative electrostatic repulsive 
forces.18 pH below 5 should be avoided, because the electro-
static repulsion between oil droplets is decreased resulting in 
the instability of the emulsion.21 In another study the cut-off 
value of pH of propofol was 3.5, as lower values resulted 
in increased instability.22 The optimum pH of the finished 
emulsion is considered to be 6–7.23 Before sterilisation small 
amounts of sodium hydroxide can be used to adjust the pH 
to be around 8. A slightly alkaline pH is required because the 
Figure 1 The average pH values of the propofol and crystalloids 
mixtures. BB, B.Braun propofol, FK, Fresenius Kabi propofol, 
UAB, UAB Norameda propofol, NS, 0.9% sodium chloride, 
ISO, Isolyte, RF, Ringerfundin, SFB, Sterofundin B, SFG, Sterofundin G, 
Mg, 10% magnesium sulphate, KCl, 10% potassium chloride.
Figure 2 The average pH values of the propofol and crystalloids 
mixtures (cont.) BB, B.Braun propofol, FK, Fresenius Kabi propofol, 
UAB, UAB Norameda propofol, NS, 0.9% sodium chloride, 
ISO, Isolyte, RF, Ringerfundin, SFB, Sterofundin B, SFG, Sterofundin G, 
Mg, 10% magnesium sulphate, KCl, 10% potassium chloride.
Figure 3 Droplet size change of propofol after mixing with crystalloids. 
BB, B. Braun propofol, FK, Fresenius Kabi propofol, UAB, UAB Norameda 
propofol, NS, 0.9% sodium chloride, ISO, Isolyte, RF, Ringerfundin, 
SFB, Sterofundin B, SFG, Sterofundin G, MgSO4, 10% magnesium sulphate, 
KCl, 10% potassium chloride.
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pH decreases during sterilisation, and on storage, due to the 
hydrolysisof glycerides and phosphatides which liberates free 
fatty acids.23 
 The average size of the oil droplets of emulsions for intra-
venous delivery is 0.150 – 0.300 µm and the optimal size is 
generally considered ≤ 1 µm18 Our investigated formulae of 
propofol had smaller droplet size compared with the results 
of Stucki et al., where the droplet size of the other propofol 
formula (Disopirovan, AstraZeneca) was 0.160 to 0.190 µm.22 
It is known that the presence of monovalent or divalent cations 
can destabilise emulsions by neutralising the repulsive negative 
charges on the droplet surfaces leading to the physical insta-
bility of emulsions. It is often manifested in change of droplet 
size, ultimately leading to flocculation, coalescence or emulsion 
breaking. There was no difference in magnesium concentration, 
when the magnesium was added as a secondary additive to 0.9% 
sodium chloride or to other crystalloids. We expected, beside 
the equal magnesium concentration (4 mg/ml), that the globe 
size would be influenced by pH and by the other electrolyte 
compounds of crystalloids. In spite of this, only the propofol of 
FK showed a slight increase in the droplet size. Although, the 
highest change in droplet size was in many FK samples, but it 
is not considered clinically relevant. In the clinical practice the 
infusions are only mixed in a brief line segment during admin-
istration trough a Y-site, consequently the contact time between 
the fluid layers is unlikely to exceed the 2 hours. We did not 
analyse the emulsions quantitatively, (e.g. HPLC), but we could 
not find any difference in the ingredients of propofol emul-
sions according to their summary of product charecteristics. 
We measured the zeta potential of three original propofol only, 
but we did not find significant difference between them, which 
can explain our results. The zeta potentials of propofol emul-
sions are the following: FK -42,5 mV, BB -40 mV,UAB -44,4 mV. 
Therefore, we agree with the assumption of Zbytovska et al., 
who state that, the stability of these mixtures can be influenced 
by the buffering capacity of the preparations.24 
 MCTs can improve the stability of lipid emulsions by 
displacing LCTs at the droplet surface and reducing stress on the 
emulsifier due to the shorter hydrocarbon chain.25 This change 
in the emulsion formulation could be the explanation, why we 
did not observe incompatibility when MCT/LCT propofols were 
mixed with magnesium despite of similar magnesium concentra-
tions were found to be incompatible with LCT propofol.22 
COnClusIOn
The practice of safe infusion administration is necessary 
particularly when simultaneous infusions are to be co-ad-
ministered. The critically ill patients are exposed to a higher 
likelihood of medication incompatibility because of a high 
number of drug combinations.This study showed that the 
investigated MCT/LCT propofol injectable emulsions are 
physically compatible with 10% magnesium-sulphate, 10 % 
potassium-chloride and different composition crystalloids 
(0,9% NaCl, Isolyte, Ringerfundin, Sterofundin B, Stero-
fundin G) during a two-hour period. In the clinical practice, 
administration of these combinations via Y-site are safe.
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